Author details

Full Name

Keith L Ligon

Affiliation

ORCID

Career Start Year

1993

Papers

279

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36847506	(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.	Cancer Discov	2023
36239925	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.	Neuro Oncol	2023
35604410	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.	Neuro Oncol	2023
37853118	Clinical trial links oncolytic immunoactivation to survival in glioblastoma.	Nature	2023
37672566	Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.		2023
37722087	Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.	J Clin Oncol	2023
37713468	Glioma genetic profiles associated with electrophysiologic hyperexcitability.		2023
37791581	Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma.		2023
37554224	Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression.	Neurooncol Adv	2023
37870091	Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors.		2023
37865722	Liquid biopsy epigenomic profiling for cancer subtyping.	Nat Med	2023
37609311	Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning.	medRxiv	2023
36780194	ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.	Clin Cancer Res	2023
37210412	Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma.		2023
37399061	Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.	Neuro Oncol	2023
37205492	Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.	bioRxiv	2023
36810872	Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment.	Sci Rep	2023
36694348	Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.	Neuro Oncol	2023
36865325	Glioma genetic profiles associated with electrophysiologic hyperexcitability.	medRxiv	2023
37171617	Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.	Cell Mol Life Sci	2023
37421953	Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma.	Med	2023
37349501	High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers.		2023
36980299	Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation.		2023
35053576	The Alliance AMBUSH Trial: Rationale and Design.	Cancers (Basel)	2022
35973991	Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma.	Nat Commun	2022
35973053	Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.	Neuro-Oncology	2022
35715666	Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.	J Neurooncol	2022
36305736	BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.	Cancer Discov	2022
36040810	VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.	JCI Insight	2022
35384518	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.	Journal of Neuro-Oncology	2022
35802025	FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.	Cancer Res	2022
35794506	CorrectionÂ to: Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.	J Neurooncol	2022
36057740	PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors.	Modern Pathology	2022
35985343	De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.	Cancer Cell	2022
35925403	Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion.	Acta Neuropathol	2022
35788723	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.	Nat Cancer	2022
35669012	Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas.	Neurooncol Adv	2022
35474499	Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.	J Neurooncol	2022
36471070	K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas.	Nat Genet	2022
36471067	The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.	Nat Genet	2022
36926246	Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.	Neurooncol Adv	2022
34015129	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.	Neuro Oncol	2022
34984433	Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.	Neuro Oncol	2022
34508644	A molecularly integrated grade for meningioma.	Neuro Oncol	2022
34389641	Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain.	Cancer Discov	2022
34383057	Multimodal platform for assessing drug distribution and response in clinical trials.	Neuro Oncol	2022
35105861	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.	Nat Commun	2022
34878541	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.	Neuro Oncol	2022
34473298	Telomerase as a therapeutic target in glioblastoma.	Neuro-Oncology	2021
33592174	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.	Cell	2021